Ovarian cancer is one of the leading cause of cancer death in women and the leading cause of death from gynecological cancer. Ovarian cancer is known as the silent killer because it frequently causes non-specific symptoms, which contribute to diagnostic delay and poor prognosis. A physical examination, blood test, or medical imaging typically leads to diagnosis of ovarian cancer.
Tumor markers, such as CA125, are proven tools for prognosis, monitoring therapy response, and early detection of recurrences of ovarian cancer. However they do not supply sufficient information for disease management.
Due to its high sensitivity for progressive disease, the activity marker TPS® provides useful supplementary information to other markers. Clinical reports show an increase in prognosis accuracy with the combination of CA125 and TPS® for monitoring. In short, the addition of TPS® improves clinical decision-making and overall patient management for ovarian cancer.